Compositions and methods for the detection and treatment of T1D are provided.

The present disclosure provides use of CDK16 as a target in preparation of a drug for treating triple-negative breast cancer. It is found through research in the present disclosure that knock down of the CDK16 can significantly inhibit the growth of TNBC xenograft tumors, PDX and PDO. Its mechanism is mainly that the knock down of the CDK16 can inhibit the phosphorylation of PRC1 (T481), prevent formation of spindles in a cell mitotic phase, and make cells unable to divide normally, thereby inhibiting the occurrence, development and metastasis of TNBC tumors. Meanwhile, it is found through research that Rebastinib, a covalent small-molecule inhibitor of the CDK16, shows a very good effect in inhibiting the development of TNBC tumors and is a potential novel drug for the treatment of TNBC.

Disclosed are a polynucleotide, a protein, a biological material, and use thereof in the improvement of the quality of a plant fruit. The polynucleotide includes any one of the sequences set forth in SEQ ID NOs: 3, 11, 23-36, and 95-108; a complementary sequence, a degenerate sequence, or a homologous sequence thereof; a sequence hybridized with the sequence or a complementary sequence thereof under rigorous conditions; and a cDNA sequence of the sequence. It is found that the gene is a key regulatory gene affecting the sugar content of the fruit, and in the use, the content of SSC, glucose, fructose, citric acid, and malic acid of the plant fruit can be regulated by regulating the protein function, the expression level, and the like of CDPK gene without significantly affecting the weight of the fruit, such that the quality and flavor of a tomato fruit are improved.